Daniel C. Chung

Affiliations: 
2003-2014 Ophthalmology University of Pennsylvania, Philadelphia, PA, United States 
Google:
"Daniel Chung"

Parents

Sign in to add mentor
Jean Bennett research scientist 2003-2014 Penn
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Leroy BP, Fischer MD, Flannery JG, et al. (2022) Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Research
Aleman TS, Huckfeldt RM, Serrano LW, et al. (2022) AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: Two Year Interim Results of an Ongoing Phase I/II Gene Therapy Trial. Ophthalmology
Maguire AM, Russell S, Chung DC, et al. (2021) Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 Years and 4 Years. Ophthalmology
Maguire AM, Russell S, Wellman JA, et al. (2019) Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. 126: 1273-1285
Sochor MA, Vasireddy V, Drivas TG, et al. (2018) Author Correction: An Autogenously Regulated Expression System for Gene Therapeutic Ocular Applications. Scientific Reports. 8: 17286
Chung DC, Bertelsen M, Lorenz B, et al. (2018) The Natural History of Inherited Retinal Dystrophy due to Biallelic Mutations in the RPE65 Gene. American Journal of Ophthalmology
Russell S, Bennett J, Wellman JA, et al. (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet (London, England)
Chung DC, McCague S, Yu ZF, et al. (2017) Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clinical & Experimental Ophthalmology
Aleman TS, Han G, Serrano LW, et al. (2016) Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study. Ophthalmology
Bennett J, Wellman J, Marshall KA, et al. (2016) Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet (London, England)
See more...